#China #N/A #ProBio #Kun Tuo #CDMO CRO

ProBio and Kun Tuo Join Forces for Integrated Solutions

In a significant development in the biopharmaceutical landscape, ProBio, a prominent global Contract Development and Manufacturing Organization (CDMO) specializing in biologics and advanced therapies, has announced a strategic partnership with Kun Tuo, a subsidiary of IQVIA and a leading Clinical Research Organization (CRO) in China. This collaboration aims to enhance Investigator-Initiated Trials (IITs) and improve clinical operations, addressing the rising demand for innovative therapeutic solutions in China.

The Purpose of the Collaboration

This partnership brings together the strengths of ProBio in product development and manufacturing and Kun Tuo’s expertise in managing complex clinical trials. Together, they will provide a comprehensive, integrated service model that spans Chemistry, Manufacturing and Controls (CMC), non-clinical studies, and clinical operations. The ultimate goal is to create a simplified and efficient development pathway for biologics and complex therapies, thereby accelerating the clinical execution timeline.

With a robust infrastructure in place, the collaboration is designed to meet the evolving needs of global biopharmaceutical companies seeking to develop new therapies. As highlighted by Allen Guo, CEO of ProBio, the need for comprehensive support throughout the drug development lifecycle is becoming increasingly prominent, particularly in light of growing global demand for advanced therapies.

Unifying Strengths

ProBio boasts an impressive track record, having produced over 1,000 GMP batches for cell and gene therapy products and supporting more than 90 Investigational New Drug (IND) approvals. This partnership will not only enhance ProBio's offerings but also help customers gain direct access to clinical operations support through Kun Tuo’s established networks and resources, making the transition from preclinical manufacturing to clinical development smoother.

Kun Tuo, with its team of approximately 1,000 employees experienced in facilitating more than 1,400 clinical trials, acts as a key player in this collaboration. Their extensive knowledge of China's clinical landscape, paired with the global operational expertise of IQVIA, positions Kun Tuo as an ideal partner for ProBio in navigating the complexities of clinical trials in this burgeoning market.

Marketing the Advantages

The unique selling proposition of this alliance lies in its ability to create a more connected ecosystem that seamlessly links development, manufacturing, and clinical execution. By streamlining these processes, the partnership aims to minimize obstacles associated with clinical trial management, such as referral friction between development and clinical phases, thus accelerating access to sites and principal investigators.

Linda Wang, General Manager of Kun Tuo, expresses excitement about collaborating with ProBio, noting the strategic alignment of their strengths to form a powerful resource for customers looking to conduct clinical trials in China efficiently and confidently.

Conclusion

By merging ProBio’s capabilities in advanced therapy manufacturing with Kun Tuo’s clinical trial expertise, the partnership looks to shape the future of biopharmaceutical development in China. This alliance not only sets a benchmark for efficiency but also ensures that the burgeoning demand for integrated IIT services in China is met effectively. Together, ProBio and Kun Tuo are poised to transform how therapeutics reach patients, marking a notable milestone in the clinical landscape.

For more information on ProBio's capabilities in cell and gene therapy and the strategic benefits of this partnership, please visit ProBio.